Entia Biosciences (ERGO) 10-K 30 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 30, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Entia Biosciences, Inc.
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		16,709,309
Entity Public Float			$3,183,009
Amendment Flag	FALSE
Entity Central Index Key	1408299
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash	$99,462	$36,886
Accounts receivable, net	243,782	11,197
Inventory, net	95,376	138,941
Interest income receivable	0	3,965
Prepaid expenses	46,107	34,462
Total Current Assets	484,727	225,451
Property and Equipment, net	43,147	62,145
Patents and license, net	342,834	343,498
Total Assets	870,708	631,094
Current Liabilities:
Accounts payable and accrued expenses	569,169	1,157,717
Short-term convertible notes payable, net of discount related-party	9,399	23,427
Short-term convertible notes payable, net of discount	357,646	373,644
Capital lease payable	0	2,105
Notes payable	51,030	23,788
Total Current Liabilities	987,244	1,580,681
Total Liabilities	987,244	1,580,681
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized, Series A preferred stock, 350,000 shares designated, 200,807 and 281,969 shares issued and outstanding, respectively, aggregate liquidation value of $1,004,035 and $1,409,845 respectively	201	282
Common stock, $0.001 par value, 150,000,000 shares authorized, 15,512,927 and 8,297,645 shares issued and outstanding, respectively.	15,514	8,298
Stock subscription receivable	0	-49,000
Additional paid-in capital	10,771,035	7,793,760
Deferred compensation	-86,344	-182,576
Accumulated deficit	-10,816,942	-8,520,351
Total Stockholders' Equity (Deficit)	-116,536	-949,587
Total Liabilities and Stockholders' Equity (Deficit)	$870,708	$631,094

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	15,512,927	8,297,645
Common stock, shares outstanding	15,512,927	8,297,645
Series A Preferred Stock [Member]
Preferred stock, shares authorized	350,000	350,000
Preferred stock, shares issued	200,807	281,969
Preferred stock, shares outstanding	200,807	281,969
Preferred stock, aggregate liquidation value (in Dollars)	$1,004,035	$1,409,845

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
REVENUES	$656,342	$314,746
COST OF GOODS SOLD	245,471	131,123
GROSS PROFIT	410,871	183,623
OPERATING EXPENSES
Advertising and promotion	125,728	171,137
Professional fees	156,561	147,469
Consulting fees	400,352	919,710
Impairment of intangible asset	27,080	288,454
General and administrative	1,499,164	1,626,873
Total Operating Expenses	2,208,885	3,153,643
LOSS FROM OPERATIONS	-1,798,014	-2,970,020
OTHER INCOME (EXPENSES)
Interest income	0	9,882
Interest expense	-339,709	-144,689
Other income (expense)	7,298	0
Loss on write-off of debt discount	-100,000	0
Loss on conversion of notes payable	-169,187	0
Gain on settlement of accounts payable	103,021	0
NET LOSS	-2,296,591	-3,104,827
DEEMED DIVIDEND RELATED TO BENEFICIAL CONVERSION FEATURE OF CONVERTIBLE PREFERRED STOCK	0	-87,600
NET LOSS PER SHARE ALLOCABLE TO COMMON STOCKHOLDERS	($2,296,591)	($3,192,427)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED: (in Dollars per share)	($0.24)	($0.42)
Weighted common shares outstanding - basic and diluted (in Shares)	9,442,352	7,533,540

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Warrants Issued in Connection with Debt [Member]	Warrants Issued in Connection with Debt [Member]	Conversion of Convertible Debt [Member]	Conversion of Convertible Debt [Member]	Conversion of Convertible Debt [Member]	Conversion of Convertible Debt [Member]	Conversion of Accounts Payable [Member]	Conversion of Accounts Payable [Member]	Conversion of Accounts Payable [Member]	Conversion of Accounts Payable [Member]	Conversion of Preferred Stock [Member]	Conversion of Preferred Stock [Member]	Conversion of Preferred Stock [Member]	Conversion of Accrued Compensation [Member]	Conversion of Accrued Compensation [Member]	Conversion of Accrued Compensation [Member]	Warrants Issued for Services [Member]	Warrants Issued for Services [Member]	Warrants Issued for Extension on Debt [Member]	Warrants Issued for Extension on Debt [Member]	Future Services [Member]	Future Services [Member]	Future Services [Member]	Future Services [Member]	Warrants Issued for Conversion of Accrued Salary [Member]	Warrants Issued for Conversion of Accrued Salary [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Deferred Compensation, Share-based Payments [Member]	Stock Subscriptions [Member]	Retained Earnings [Member]	Total
	Additional Paid-in Capital [Member]		Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]		Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]		Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]		Additional Paid-in Capital [Member]	Deferred Compensation, Share-based Payments [Member]	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]	Deferred Compensation, Share-based Payments [Member]		Additional Paid-in Capital [Member]
Balance at Dec. 31, 2012																											$110	$7,444	$5,115,587	($394,510)	($49,000)	($5,327,924)	($648,293)
Balance (in Shares) at Dec. 31, 2012																											109,900	7,444,591
Issuance of stock for cash																											140		700,735				700,875
Issuance of stock for cash (in Shares)																											140,175
Issuance of preferred stock for cancellation of debt																											3		15,747				15,750
Issuance of preferred stock for cancellation of debt (in Shares)																											3,162
Issuance of warrants	16,400	16,400															584,108	-584,108	98,006	98,006
Amortization of deferred compensation																														796,042			796,042
Net loss																																-3,104,827	-3,104,827
Beneficial conversion feature in connection with convertible note																													64,956				64,956
Issuance of stock for conversion			23		116,629	116,652	31		151,970	152,001	-25	250	-225	274	129,727	130,001
Issuance of stock for conversion (in Shares)			23,332				30,400				-25,000	250,000		273,158
Stock compensation																													413,921				413,921
Issuance of common stock for services																												130	83,270				83,400
Issuance of common stock for services (in Shares)																												129,896
Issuance of common stock & warrants for license agreement																												200	215,329				215,529
Issuance of common stock & warrants for license agreement (in Shares)																												200,000
Deemed dividend related to beneficial conversion feature of convertible preferred stock																													87,600			-87,600
Balance at Dec. 31, 2013																											282	8,298	7,793,760	-182,576	-49,000	-8,520,351	-949,587
Balance (in Shares) at Dec. 31, 2013																											281,969	8,297,645
Issuance of stock for cash																												525	224,475				225,000
Issuance of stock for cash (in Shares)																												525,000					525,000
Issuance of warrants	88,600	88,600															153,010	-153,010							91,863	91,863
Amortization of deferred compensation																														293,492			293,492
Net loss																																-2,296,591	-2,296,591
Beneficial conversion feature in connection with convertible note																													188,300				188,300
Issuance of stock for conversion				2,634	930,650	933,284		345	132,583	132,928	-81	812	-731	2,592	775,178	777,770
Issuance of stock for conversion (in Shares)				2,633,579				344,530			-81,162	811,620		2,592,570
Stock compensation																													227,570				227,570
Issuance of common stock for services																					68	44,182	-44,250	44,250				240	121,595				121,835
Issuance of common stock for services (in Shares)																					68,283			68,283				239,700
Receipt of stock subscription receivable, less write-off of $9,000																															49,000		49,000
Balance at Dec. 31, 2014																											$201	$15,514	$10,771,035	($86,344)		($10,816,942)	($116,536)
Balance (in Shares) at Dec. 31, 2014																											200,807	15,512,927

CONSOLIDATED_STATEMENT_OF_STOC1

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) (Stock Subscriptions [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Stock Subscriptions [Member]
Stock subscription receivable, write-off	$9,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($2,296,591)	($3,104,827)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	30,022	0
Depreciation/amortization	38,047	35,990
Gain on settlement of accounts payable	-103,021	0
Impairment of intangible asset	27,080	288,454
Loss on write-off of debt discount	100,000	0
Amortization of discount on convertible notes	120,387	107,455
Loss on conversion of debt	169,187	0
Stock-based compensation	642,897	1,293,363
Loss on sale of stock subscription receivable	12,965	0
Changes in operating assets and liabilities:
Accounts receivable	-262,607	-30,725
Inventory	43,565	-15,808
Prepaid expenses	31,668	-1,920
Other current assets	0	118
Accounts payable and accrued expenses	766,117	661,167
NET CASH USED IN OPERATING ACTIVITIES	-680,284	-766,733
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	-4,607	-52,548
Acquisition of patents and patents pending (net)	-40,857	-12,056
NET CASH USED IN INVESTING ACTIVITIES	-45,464	-64,604
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, preferred stock and warrants	225,000	700,875
Proceeds from convertible notes payable and notes payable	591,500	151,099
Payment on notes payable, net	-43,176	-36,832
Payment on convertible note payable - related party	-40,000	0
Proceeds from sale of stock subscription receivable	40,000	0
Proceeds from convertible note payable-related party	15,000	40,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	788,324	855,142
NET CHANGE IN CASH	62,576	23,805
Cash at beginning of period	36,886	13,081
Cash at end of period	99,462	36,886
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	843	1,064
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Stock issued for accounts payable	132,928	0
Deemed distribution	0	87,600
Conversion of accrued compensation, notes payable and accrued interest to preferred and common stock	1,711,054	414,404
Issuance of warrants for accrued salary	91,863	0
Stock and Warrant Issued for Inventory [Member]
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Stock & warrant issued	0	9,000
Stock and Warrant Issued for License [Member]
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Stock & warrant issued	0	215,529
Note Issued for Insurance [Member]
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Issuance of debt	43,313	0
Note Issued for License [Member]
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING AND INVESTING ACTIVITIES:
Issuance of debt	$0	$140,000

NOTE_1_ORGANIZATION_AND_OPERAT

NOTE 1 - ORGANIZATION AND OPERATIONS	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – ORGANIZATION AND OPERATIONS
	We engage in the distribution of organic dietary supplement nutraceutical products in the United States of America.  We are also engaged in the discovery, scientific evaluation and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics and other products developed and sold by Entia and by third parties.
	We have a history of incurring net losses and net operating cash flow deficits.  We are also developing new technologies related to our organic nutraceutical products and we have executed an agreement with a distributor that has a nation-wide chain of salons.  At December 31, 2014, we had cash and cash equivalents of $99,462.  These conditions raise substantial doubt about our ability to continue as a going concern.  As a result, we anticipate that our cash and cash equivalent balances, anticipated cash flows from operations and anticipated operating cash flows will be sufficient to meet our cash requirements through June 2015.
	In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs.  The issuance of equity securities will cause dilution to our shareholders.  If external financing sources of financing are not available or are inadequate to fund our operations, we will be required to reduce operating costs including personnel costs, which could jeopardize our future strategic initiatives and business plans.  The accompanying consolidated financial statements have been prepared assuming that the company continues as a going concern.
	The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

NOTE_2_SUMMARY_OF_SIGNIFICANT_

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation and principles of consolidation
	The accompanying consolidated financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP).  Material intercompany transactions and balances have been eliminated in consolidation.
	The consolidated financial statements include the accounts of Entia and Total Nutraceutical Solutions, a wholly-owned subsidiary, as of December 31, 2014 and 2013.
	Use of estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
	Cash
	We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.
	Accounts receivable
	Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts.  The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable.  Outstanding account balances are reviewed individually for collectibility.  We determine the allowance based on historical write-off experience, customer specific facts and economic conditions.  Bad debt expense is included in general and administrative expenses, if any.  We generally consider accounts greater than 30 days old to be past due.  Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote.  The allowance for doubtful accounts was $30,022 and $2,526 at December 31, 2014 and 2013, respectively.
	Inventory
	Inventory, which consists primarily of raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the average cost method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory.
	Property and equipment
	Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred.  Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations.  Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Office equipment	3 years
	Production equipment	5 to 7 years
	Leasehold improvements	Lesser of lease term or useful life of improvement
	Patents
	Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs.  Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected.  The costs of defending and maintaining patents are expensed as incurred.  Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
	Impairment of long-lived assets
	Our long-lived assets, which include property and equipment, patents and licenses of patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
	We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets.  Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.  If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.
	We have recorded an impairment on our intangibles in the amount of $27,080 and $288,454 on December 31, 2014 and 2013, respectively.
	Discount on convertible notes payable
	We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument.  The amortization is recorded as interest expense on the consolidated statement of operations.
	Fair value of financial instruments
	The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable approximate their fair values determined based on level 1 inputs in the fair value hierarchy because of the short maturity of these instruments.  Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes.
	Fair value measurements
	We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1		Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2		Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3		Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at December 31, 2014 or 2013, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the years ended December 31, 2014 and 2013.
	Revenue recognition
	We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured.
	Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers and distributors. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive.  Allowances for product returns, primarily in connection with one distribution agreement, are provided at the time the sale is recorded.  This allowance is based upon historical return rates for the Company and relevant industry patters, which reflects anticipated returns of unopened product in its original packaging to be received over a period of 120 days following the original sale.
	Shipping and handling costs
	Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred.  In 2014 and 2013, we incurred $34,286 and $31,996, respectively, in shipping costs included in cost of goods sold.
	Advertising costs
	Costs associated with the advertising of our products are expensed as incurred.
	Research and development
	Research and development costs are charged to expense as incurred.  Research and development costs consist primarily of material and testing costs for research and development as well as research and development arrangements with unrelated third party research and development institutions.  These research and development arrangements usually involve one specific research and development project.  We may make non-refundable advances upon signing of these arrangements.  Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.  Such amounts are recognized as an expense as the related goods are delivered or as the related services are performed.  Management periodically evaluates whether the goods will be delivered or services will be rendered.  If management does not expect the goods to be delivered or services to be rendered, the capitalized advance payment is charged to expense.  Research and development expense was $24,523 and $27,804 in 2014 and 2013, respectively and are classified as general and administrative on the consolidated statements of operations.
	Equity instruments issued to parties other than employees for acquiring goods or services
	We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  Currently such transactions are primarily awards of warrants to purchase common stock.
	The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model.
	The assumptions used to determine the fair value of our warrants are as follows:
	-	The expected life of warrants issued represents the period of time the warrants are expected to be outstanding.
	-	The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant.
	-	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant.
	-	The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant.
	Income taxes
	We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.  Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense.
	The tax years that are open to examination are 2011, 2012, 2013 and 2014.
	Net loss per common share
	Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2014 and 2013. The following table presents a reconciliation of basic loss per share and excluded dilutive securities:
			For the Years Ended
			2014			2013
	Numerator:
	Net loss allocable to common stockholders		$	(2,296,591	)	$	(3,192,427	)
	Denominator:
	Weighted-average common shares outstanding			9,442,352			7,533,540
	Basic and diluted net loss per share		$	(0.24	)	$	(0.42	)
	Common stock warrants			7,111,027			4,058,050
Series A convertible preferred stock			2,008,070			2,819,690
Stock options			2,976,670			2,352,099
Convertible debt including interest			1,317,604			932,332
Excluded dilutive securities			13,413,371			10,162,171
Reclassifications
Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation.
Segments
We have determined that we operate in one segment for financial reporting purposes.
Recently issued accounting pronouncements
In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements.

NOTE_3_INVENTORY

NOTE 3 - INVENTORY	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 3 – INVENTORY
	Inventory consists of the following at:
		31-Dec-14			31-Dec-13
	Raw materials	$	202,591		$	240,750
	Finished goods		43,849			49,255
			246,440			290,005
	Less:  reserve for excess and obsolete inventory		(151,064	)		(151,064	)
		$	95,376		$	138,941
	We recorded a reserve adjustment of $0 for excess inventory in 2014 and 2013.

NOTE_4_PROPERTY_AND_EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT
	Property and equipment, stated at cost, consists of the following at:
		31-Dec-14			31-Dec-13
	Office equipment	$	27,507		$	26,284
	Production equipment		86,999			83,615
	Leasehold improvements		16,328			16,328
			130,834			126,227
	Less:  accumulated depreciation		(87,687	)		(64,082	)
		$	43,147		$	62,145
	Depreciation expense was $23,605 and $25,327 for the years ended December 31, 2014 and 2013, respectively.

NOTE_5_PATENTS_AND_LICENSES_NE

NOTE 5 - PATENTS AND LICENSES, NET	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 5 – PATENTS AND LICENSES, NET
	Our identifiable long-lived intangible assets are patents and prepaid licenses.  On July 23, 2013, we were issued a patent in the United States.  We have begun amortizing this patent on this date for a period of 15 years.  The amount capitalized is $31,325.  On May 1, 2013, we entered into an exclusive license agreement with Penn State Research Foundation (PSRF) for 15 years to market and sell product under a patent issued to PSRF in the United States.  We incurred a license fee of $150,000 for this agreement and we are amortizing it over the life of the agreement.  In addition, in December 2013, we acquired indefinite-lived intangibles from a customer in exchange for stock and warrants.  Total value of $288,454 for the intangibles were recorded to patents and licenses and are not subject to amortization, but are subject to impairment.  Management has recorded an impairment of $288,454 for year ended 2013.   During 2014, management analyzed our intangibles for possible impairment.  We have recorded for 2014 an impairment in the amount of $27,080.
	The licenses are being amortized over an economic useful life of 15-17 years. The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at:
		31-Dec-14			31-Dec-13
	Licenses and amortizable patents	$	207,244		$	234,324
	Unamortized patents		166,159			125,301
	Accumulated amortization		(30,569	)		(16,127	)
	Patents and Licenses, net	$	342,834		$	343,498
	License amortization expense was $14,442 and $10,663 for the years ended December 31, 2014 and 2013, respectively.   Annual aggregate amortization expense for our licenses for each of the next five years through December 31, 2019, is $13,488 per year and for years 2020 and later it is estimated to be $109,235.

NOTE_6_ACCOUNTS_PAYABLE_AND_AC

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accrued expenses (included with accounts payable) consisted of the following at:
		31-Dec-14		31-Dec-13
	Executive compensation	$	153,432	$	476,368
	Other accruals		19,725		60,671
		$	173,157	$	537,039
	During third quarter, 2014, we negotiated agreements with our employees to accept either warrants or shares of common stock for conversion of their accrued payroll.  The conversion rate for the warrants or common stock would be at $0.30 per share.  During third quarter, we issued 2,592,570 shares of common stock to our key employees for conversion of $777,770 of accrued compensation.  In addition, we granted 10 year warrants to purchase 306,208 of common stock exercisable at $0.0001 per share.  These warrants fully vested on date of grant and had a grant date fair value of $91,863.

NOTE_7_NOTES_PAYABLE

NOTE 7 - NOTES PAYABLE	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 7 – NOTES PAYABLE
	Notes payable consists of the following at:
			31-Dec-14		31-Dec-13
	Notes payable - current
	7.85% unsecured, $781 due monthly		$	2,304	$	1,964
	4.15% unsecured, $2,678 due monthly			-		21,824
	4.15% unsecured, $3,436 due monthly			23,726		-
	10.00% unsecured, interest only, due on demand			25,000		-
			$	51,030	$	23,788
			31-Dec-14		31-Dec-13
	Convertible notes payable, net
	8%, unsecured due on demand (net of discount related to beneficial conversion feature of $0 in 2014 and $49,004 in 2013), convertible into common stock at $0.45 per share.  This note was converted into common stock during December 2014.		$	-	$	263,496
	8% secured due on December 26, 2015 (net of discount related to beneficial conversion feature of $7,746 in 2014 and $12,300 in 2013), convertible into preferred stock at $5.00 per share.			42,254		37,700
	6% unsecured, convertible into common stock at $2.00 per share, due on demand			50,000		50,000
	8% unsecured due August 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $40,552 in 2013), convertible into common stock at an average price of $0.205 per share  This note was converted into 419,355 shares of common stock during August 2014.			-		22,448
	10% unsecured due March 2015 (net of discount related to warrants of $2,362 in 2014 and $0 in 2013) convertible price not yet determined			22,638		-
	10% unsecured due April 2015 (net of discount related to warrants of $9,800 in 2014 and $0 in 2013) convertible price not yet determined			90,200		-
	10% unsecured due April 2015 (net of discount related to warrants of $1,377 in 2014 and $0 in 2013) convertible price not yet determined			8,623		-
	8% unsecured due April 2015 (net of discount related to beneficial conversion feature of $11,968 in 2014 and $40,552 in 2013), convertible price not yet determined			30,532		-
	8% unsecured due May 2015 (net of discount related to beneficial conversion feature of $19,190 in 2014 and $0 in 2013), convertible price not yet determined			33,810		-
	10% unsecured due December 2015 (net of discount related to warrants of $4,620 in 2014 and $0 in 2013) convertible price not yet determined			25,380		-
	10% unsecured due December 2015 (net of discount related to warrants of $1,727 in 2014 and $0 in 2013) convertible price not yet determined			8,273		-
	10% unsecured due October 2015 (net of discount related to warrants of $1,805 in 2014 and $0 in 2013) convertible price not yet determined			8,195		-
	10% unsecured due October 2015 (net of discount related to warrants of $4,512 in 2014 and $0 in 2013) convertible price not yet determined			20,488		-
	8% unsecured due September 2015 (net of discount related to beneficial conversion feature of $36,247 in 2014 and $0 in 2013), convertible price not yet determined			17,253		-
			$	357,646	$	373,644
			31-Dec-14		31-Dec-14
	Convertible notes payable, net related party
	0% unsecured due March 30, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $16,573 in 2013) convertible into common stock at $0.65 per share.  This note was paid off on March 31, 2014.		$	-	$	23,427
	0% unsecured due November 2015 (net of discount related to beneficial conversion feature of $2,738 in 2014 and $0 in 2013 and net of discount related to warrants of $2,863 in 2014 and $0 in 2013 and convertible into common stock at $0.30 per share.		$	9,399	$	-
			$	9,399	$	23,427
	In 2010, we entered into a promissory note for $312,500.  We have been successful at negotiating extensions each year on this note by granting warrants to purchase shares of common stock at various prices.  On December 31, 2014, we were successful in negotiating a conversion of the note plus accrued interest in the amount of $76,427 into 864,282 shares of common stock.  In addition to the stock, we agreed to issue new warrants valued at $374,464.  We also agreed to modify the terms of the existing warrants to the investor.  Original terms of the warrants were an exercise price of $0.45 and a term of five years.  Under the new terms, the exercise price was reduced to $0.01.  We calculated a loss of $164,934 on the conversion of the debt.  This loss is recorded in other income/(expense) on the consolidated statements of operations.
	On August 13, 2013, we entered into a promissory note for one year at 8% in the principal amount of $50,000.  The note is convertible into the Series A Preferred stock at $5.00 per share and we granted the creditor warrants to purchase 50,000 shares of Entia’s common stock at $2.00 per share.  This note was due in August 2014 and, on December 26, 2014 we were successful in extending this note through December 2015.  We granted the creditor 50,000 warrants to purchase 50,000 shares of Entia’s common stock at $0.50 per share.  We calculated and posted a discount of $8,450 on the expense related to the warrants.  We will amortize this discount over the life of the note to interest expense.  During 2014, we expensed $704 on this discount.
	During first quarter 2014, we entered into a promissory note for $25,000 at 10% interest due on December 30, 2014.  This note is not convertible and is listed with notes payable as a short-term liability on the balance sheet.  This note is currently being negotiated for an extension.
	On August 28, 2014, we entered into a convertible promissory note for $100,000.  The note was convertible into common stock at $0.25 per share.  The investor converted the notes right away and received 400,000 shares of common stock.  Following the conversion, we wrote off the debt discount for a loss of $100,000.  We have recorded this as an expense on our consolidated statements of operations.
	During 2014, we entered into the following debenture agreements that accrue interest at 10%, mature between 1 year and eighteen months and grant the investor on a one warrant per dollar basis that are exercisable for 3 years at $1 per share and vest immediately:
	o	On October 16, 2014, we entered into two agreements totaling $35,000.  We calculated the fair value of the warrants as $7,980.
	o	On September 2, 2014, we entered into an agreement for $10,000.  We calculated the fair value of the warrants at $2,590.
	o	On August 28, 2014, we entered into an agreement for $30,000.  We calculated the fair value of the warrants at $7,920.
	o	On April 15, 2014, we entered into an agreement for $10,000.  We calculated the fair value of the warrants at $4,130,
	o	On April 27, 2014, we entered into an agreement for $100,000.  We calculated the fair value of the warrants at $39,200, and
	o	On March 28, 2014, we entered into an agreement for $25,000.  We calculated the fair value of the warrants at $9,450.
	We posted the fair value of the warrants as a discount on the notes and amortize them over the life of the debenture.
	In addition to the debentures, during 2014, we entered into the following convertible promissory notes with an interest rate of 8% per annum, compounded annually.  If the note remains unpaid after one hundred eighty (180) days from the Issue date, the holder has the option to convert the principal and accrued interest into shares of our Company stock at a conversion price equal to 58% of the “trading price” as described in the note.  We have calculated a discount for the beneficial conversion feature and will be amortized over the life of the loan.
	o	On February 3, 2014, $42,500 due on November 3, 2014,
	o	On April 17, 2014, $32,500 due on January 17, 2015,
	o	On June 13, 2014, $32,500 due on March 13, 2015,
	o	On July 14, 2014, $42,500 due on April 13, 2015,
	o	On August 11, 2014, $53,000 due on May 10, 2015, and
	o	On December 15, 2014, $53,500 due on September 14, 2015.
	On March 25, 2014, we entered into a line of credit arrangement.  The line of credit is $60,000 with an interest rate of prime plus 3.00%, resulting in an interest rate of 6.25% at December 31, 2014.  There are no loan covenants applicable to this line of credit and the amount outstanding as of December 31, 2014 is $16,179.  This is reported as a current liability on the balance sheet.

NOTE_8_RELATED_PARTY_TRANSACTI

NOTE 8 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 – RELATED PARTY TRANSACTIONS
	Debt agreements from board member
	In December 2013, we entered into a promissory note due on March 31, 2014 at 0% in the principal amount of $40,000 with Dr. Philip Sobol, a member of our board of directors.  The note was paid off on March 31, 2014.
	On July 1, 2014, we entered into a promissory note due on October 31, 2014 at 0% in the principal amount of $15,000 with Dr. Philip Sobol, a member of our board of directors.  In conjunction with the note, we granted Dr. Sobol a five year warrant to purchase 15,000 shares of common stock at $0.50 per share and fully vests upon receipt of monies.  We calculated a discount on the granting of the warrants in the amount of $5,445 and expensed this during the third quarter to interest expense.  The note also contained a conversion feature where Dr. Sobol can convert the note into common stock at $0.50 per share.  We calculated and posted a discount related to this conversion feature of $7,545 and amortized it during the third quarter 2014.  During third quarter 2014, we agreed to an extension of the note until November 2015.  In exchange for the extension, we issued a seven year warrant to purchase 15,000 shares of Entia’s common stock at $0.20 per share.  The extension also changed the conversion price on the note from $0.50 per share to $0.30 per share.  We posted a discount related to the new warrants of $3,435 and will amortize this over the life of the loan to interest expense.  In addition, we also calculated the difference in fair value related to the modification of the conversion price.  We calculated a $27 difference and management decided not to post this loss.
	Preferred stock purchase from board member
	During the first quarter 2013, a board member purchased 1,000 shares of Series A Preferred stock for $5,000 cash.

NOTE_9_STOCKHOLDERS_EQUITY_DEF

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 – STOCKHOLDERS’ EQUITY (DEFICIT)
	Preferred Stock
	On May 26, 2011, our board of directors designated 350,000 shares of preferred stock as Series A preferred stock, $0.001 par value.  The Series A preferred stock is entitled to a liquidation preference in the amount of $5 per share, votes on an as converted basis with the common stock on all matters as to which holders of common stock shall be entitled to vote, and is convertible into common stock on a one-for-ten basis.
	During 2014, 5 investors converted a total of 81,162 share of Series A Preferred stock for 811,620 shares of common stock.
	During 2013, we issued the following:
	·	140,175 shares were issued for cash proceeds of $700,875;
	·	30,400 shares for conversion of $152,001 of accounts payable; and
	·	26,494 shares for conversion of $132,402 of debt and accrued interest.
	25,000 shares of the Series A Preferred stock were converted during 2013 into 250,000 shares of our common stock.
	Common stock
	During 2014, we issued shares of common stock per the following:
	·	2,633,579 shares with a value of $933,284 in exchange for conversion of notes payable in the amount of $590,882 and accrued interest of $83,247;
	·	811,620 shares were issued from conversion of 81,162 shares of Series A Preferred stock;
	·	344,530 shares were issued for settlement of accounts payable in the amount of $132,928;
	·	2,592,570 shares were issued in exchange for converting $777,770 of accrued salary to two key employees;
	·	68,283 shares were issued with a value of $44,250 for services to be performed in the future;
	·	189,700 shares were issued with a value of $100,335 for services rendered;
	·	50,000 shares were issued in conjunction with a distributor agreement valued at $21,500.  This amount is posted as a reduction in revenues; and
	·	525,000 shares were issued for cash with a value of $225,000.
	During 2013, we issued shares of common stock per the following:
	·	264,158 shares with a value of $125,001 in exchange for accrued payroll by two of our officers;
	·	250,000 shares were issued from conversion of 25,000 shares of Series A Preferred stock;
	·	53,500 shares with a value of $31,090 to vendors in association with consulting agreements signed in 2013;
	·	9,000 shares with a value of $4,320 in association with a consulting agreement signed August 1, 2013;
	·	200,000 shares with a value of $124,000 for the purchase of a license agreement; and
	·	76,396 shares with a value of $48,893 in association with employment agreements dated 2011 for two officers.
	Stock incentive plan
	On September 17, 2010, our Board of Directors adopted the Total Nutraceutical Solutions, Inc. 2010 Stock Incentive Plan (“Plan”). The Plan provides for the grant of options to purchase shares of our common stock, and stock awards consisting of shares of our common stock, to eligible participants, including directors, executive officers, employees and consultants of the Company.  We have reserved 1,550,000 shares of common stock for issuance under the Plan with an annual increase in shares of 50,000 as of January 1 of each year; commencing January 1, 2012.  Stock options are granted at or below the closing price of our stock on the date of grant for terms ranging from four to fifteen years and generally vest over a five year period.  The fair value of the option grants were calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions:
			31-Dec-14				31-Dec-13
	Expected dividend yield			-				-
	Expected stock price volatility			182.94%-216.96	%			216.96% - 236.55	%
	Risk-free interest rate			0.28% - 1.91	%			0.95% - 2.47	%
	Expected term (in years)		3 - 7 years				5 - 10 years
	Weighted-average granted date fair value		$	0.52			$	0.45
	A summary of option activity under the stock option plan as of December 31, 2014, and changes during the year then ended is presented below:
												Weighted
										Weighted		Average
										Average		Remaining		Aggregate
			Number of				Exercise Price			Exercise		Contractual Term		Intrinsic
			Shares				Range			Price		(Years)		Value
	Outstanding, December 31, 2012			1,202,099			$	0.40 - $1.00		$	0.56		7.74		-
	Exercisable, December 31, 2012			830,504			$	0.40 - $1.00		$	0.57		8.19		-
	Granted			1,150,000			$	0.38 - $0.81		$	0.47		8.07		-
	Exercised			-				-		$	-		-		-
	Expired			-				-		$	-		-		-
	Outstanding, December 31, 2013			2,352,099			$	0.38 - $1.00		$	0.51		7.9		199,505
	Exercisable, December 31, 2013			1,810,344			$	0.38 - $1.00		$	0.52		7.88		138,707
	Granted			624,571			$	0.40-$0.75		$	0.52		6.49		-
	Exercised			-				-		$	-		-		-
	Expired/Forfeited			110,200			$	0.40-$0.50		$	0.48		9.51		-
	Outstanding, December 31, 2014			2,866,470			$	0.30 - $1.00		$	0.48		8.96		-
	Exercisable, December 31, 2014			2,321,001			$	0.38 - $1.00		$	0.47		9.5		-
	The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at December 31, 2014 are as follows:
	Number of				Exercise
	shares				Price
		300,000			$	0.3
		55,000			$	0.38
		1,176,670			$	0.4
		30,000			$	0.42
		20,000			$	0.44
		10,000			$	0.45
		731,800			$	0.5
		160,000			$	0.6
		15,000			$	0.62
	120,000			$	0.75
	10,000			$	0.81
	200,000			$	0.85
	38,000			$	1
	2,866,470
At December 31, 2014, the Company had 1,783,530 unissued shares available under the Plan.  Also, at December 31, 2014, the Company had $303,349 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of 9 years.
Warrants
Outstanding warrants to purchase common stock are as follows:
Date of Issue		31-Dec-14				Exercise Price			Expiration
14-Dec			2,183,867			$	0.01 - $0.30		Dec-19
14-Nov			1,875			$	0.2		Nov-21
14-Oct			636,126			$	0.01 - $1.00		10/2017 - 10/2021
14-Sep			316,208			$	0.001 - $1.00		09/2017 - 09/2024
14-Aug			80,000			$	0.50 - $1.00		8/2017 - 8/2019
14-Jun			15,000			$	0.5		Jun-19
14-Apr			110,000				1		Apr-17
14-Mar			38,332			$	0.40 - $1.00		03/2017 - 02/2024
14-Jan			33,943			$	0.60 - $0.80		01/2019 - 01/2021
As of December 2013			4,500,896			$	0.36 - $10.00		05/2015 - 10/2024
Total			7,916,247
Less:
Expired			805,220
Exercised			-
Total			7,111,027
We use the Black-Scholes option-pricing model to determine the fair value of warrants on the date of grant.
In determining the fair value of warrants, we employed the following key assumptions:
		31-Dec-14				31-Dec-13
Risk-Free interest rate			0.28% - 2.97	%			0.95% - 3.32	%
Expected dividend yield			0	%			0	%
Volatility			182.81% - 222.30	%			216.48% - 239.20	%
Expected life		3 - 10 years				3 - 10 years
At December 31, 2014 and 2013, the weighted-average Black-Scholes value of warrants granted was $0.39 and $0.45, respectively.

NOTE_10_INCOME_TAXES

NOTE 10 - INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 10 – INCOME TAXES
	For the years ended December 31, 2014, and 2013, we incurred net operating losses and, accordingly, no provision for income taxes has been recorded.   In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets.   At December 31, 2014, we had approximately $4,382,132 of net operating losses. The net operating loss carryforwards, if not utilized, will begin to expire in 2026.
	The components of our deferred tax assets/liabilities as of December 31, are as follows:
		2014			2013
	Deferred tax assets:
	Reserves and accruals	$	114,000		$	188,000
	Net operating loss carryforwards		1,472,000			1,149,000
	Total deferred tax assets:		1,586,000			1,337,000
	Deferred tax liabilities:
	Depreciation and amortization		8,000			11,000
	Net deferred tax assets before valuation allowance		1,578,000			1,326,000
	Less:  Valuation allowance		(1,578,000	)		(1,326,000	)
	Net deferred tax assets	$	-		$	-
	For financial reporting purposes, we have incurred a loss in each period since inception. Based on the available objective evidence, including our history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable.   Accordingly, we provided for a full valuation allowance against our net deferred tax assets at December 31, 2014, and 2013.  A reconciliation between the amount of income tax benefit determined by applying the applicable U.S. statutory income tax rate to pre-tax loss for the years ended December 31, is as follows:
		2014			2013
	Federal Statutory Rate	$	(781,000	)	$	(1,056,000	)
	Nondeductible expenses		529,000			683,000
	Change in allowance on deferred tax assets		(252,000	)		(373,000	)
		$	-		$	-

NOTE_11_COMMITMENTS_AND_CONTIN

NOTE 11 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 – COMMITMENTS AND CONTINGENCIES
	Leases
	On April 4, 2012, the Company entered into a Commercial Lease agreement with Lanz Properties, LLC for 13,081 square feet of office and warehouse space located at 13565 SW Tualatin-Sherwood Road, Suite 800, Sherwood, OR 97140.  The new lease commenced on June 1, 2012 and will terminate on July 31, 2015.  No rent was payable until October 2012.  The base monthly rental rate started at $3,160, increasing to $3,260 in October 2013, and then $3,343 in June 2014.  The Company has straight-lined the full value of the lease agreement over the life of the lease and has recorded this amount monthly.  The amount of rent expense that is above the actual rent amount is recorded as deferred rent and is shown on the balance sheet in current liabilities as part of accounts payable and accrued expenses. The amount recorded for 2014 is $1,279 and $6,555 for 2013.
	Future minimum lease payments for all of our facilities amount to $47,988 each year through 2014 and $27,992 for 2015.  Rent expense for the years ended December 31, 2014 and 2013 was $47,988 and $43,497, respectively.

NOTE_12_CONCENTRATIONS_AND_CRE

NOTE 12 - CONCENTRATIONS AND CREDIT RISK	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 12 – CONCENTRATIONS AND CREDIT RISK
	Customers and Credit Concentrations
	During 2014, approximately 47% of our sales were to 5 customers as compared to approximately 50% during 2013.  Accounts receivable for these customers accounted for 81% and 31% of total accounts receivable at December 31, 2014 and 2013, respectively.
	Vendor Concentrations
	During 2014, approximately 46% of our purchases were made from 5 vendors as compared to 54% during 2013.  Accounts payable for these vendors accounted for 4% and 1% of total accounts payable at December 31, 2014 and 2013, respectively.

NOTE_13_SUBSEQUENT_EVENTS

NOTE 13 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 – SUBSEQUENT EVENTS
	On January 15, 2015, a creditor converted $15,000 of a promissory note in exchange for 170,068 shares of common stock.
	On February 4, 2015, a creditor converted the remaining $27,500 of a promissory note plus $1,700 of accrued interest in exchange for 357,843 shares of common stock.  In conjunction with this conversion, we wrote-off the remaining $11,968 of debt discount to interest expense during first quarter 2015.
	On February 19, 2015, a creditor converted $25,000 of a promissory note in exchange for 318,471 shares of common stock.
	On February 24, 2015, we paid off the remaining $28,000 of a promissory note.  In addition, we paid $2,171 of accrued interest and $12,329 in a pre-payment penalty in connection with the repayment.  In conjunction with this conversion/pay off, we wrote-off the remaining $19,190 of debt discount to interest expense during first quarter 2015.
	On January 9, 2015, we received $20,000 for 100,000 shares of common stock and 20,000 warrants to purchase common stock.  The warrants are exercisable at $0.30 per share.  The term of the warrants are for 5 years and vest immediately.
	On January 2, 2015, we received $20,000 for 100,000 shares of common stock and 20,000 warrants to purchase common stock.  The warrants are exercisable at $0.30 per share.  The term of the warrants are for 5 years and vest immediately.
	On January 30, 2015, we received $30,000 for 150,000 shares of common stock and 30,000 warrants to purchase common stock at $0.30 per share.  The terms of the warrants are for 5 years and vest immediately.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation and principles of consolidation
	The accompanying consolidated financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP).  Material intercompany transactions and balances have been eliminated in consolidation.
	The consolidated financial statements include the accounts of Entia and Total Nutraceutical Solutions, a wholly-owned subsidiary, as of December 31, 2014 and 2013.
Use of Estimates, Policy [Policy Text Block]	Use of estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash
	We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.
Receivables, Policy [Policy Text Block]	Accounts receivable
	Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts.  The allowance for doubtful accounts is our best estimate of the amount of probable credit losses based on specific identification of accounts in our existing accounts receivable.  Outstanding account balances are reviewed individually for collectibility.  We determine the allowance based on historical write-off experience, customer specific facts and economic conditions.  Bad debt expense is included in general and administrative expenses, if any.  We generally consider accounts greater than 30 days old to be past due.  Account balances are charged off against allowance after all means of collection have been exhausted and the potential for recovery is considered remote.  The allowance for doubtful accounts was $30,022 and $2,526 at December 31, 2014 and 2013, respectively.
Inventory, Policy [Policy Text Block]	Inventory
	Inventory, which consists primarily of raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the average cost method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment
	Property and equipment are recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred.  Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in the consolidated statement of operations.  Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Office equipment	3 years
	Production equipment	5 to 7 years
	Leasehold improvements	Lesser of lease term or useful life of improvement
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents
	Patents, once issued or purchased, are amortized using the straight-line method over their economic remaining useful lives. All internally developed process costs incurred to the point when a patent application is to be filed are expensed as incurred and classified as research and development costs.  Patent application costs, generally legal costs, are capitalized pending disposition of the individual patent application, and are subsequently either amortized based on the initial patent life granted, generally 15 to 20 years for domestic patents and 5 to 20 years for foreign patents, or expensed if the patent application is rejected.  The costs of defending and maintaining patents are expensed as incurred.  Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of long-lived assets
	Our long-lived assets, which include property and equipment, patents and licenses of patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
	We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets.  Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.  If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.
	We have recorded an impairment on our intangibles in the amount of $27,080 and $288,454 on December 31, 2014 and 2013, respectively.
Debt, Policy [Policy Text Block]	Discount on convertible notes payable
	We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument.  The amortization is recorded as interest expense on the consolidated statement of operations.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments
	The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable and accounts payable approximate their fair values determined based on level 1 inputs in the fair value hierarchy because of the short maturity of these instruments.  Due to conversion features and other terms, it is not practical to estimate the fair value of notes payable and convertible notes.
Fair Value Measurement, Policy [Policy Text Block]	Fair value measurements
	We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1		Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2		Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3		Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at December 31, 2014 or 2013, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the years ended December 31, 2014 and 2013.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition
	We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured.
	Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers and distributors. Persuasive evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive.  Allowances for product returns, primarily in connection with one distribution agreement, are provided at the time the sale is recorded.  This allowance is based upon historical return rates for the Company and relevant industry patters, which reflects anticipated returns of unopened product in its original packaging to be received over a period of 120 days following the original sale.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and handling costs
	Amounts charged to customers for shipping products are included in revenues and the related costs are classified in cost of goods sold as incurred.  In 2014 and 2013, we incurred $34,286 and $31,996, respectively, in shipping costs included in cost of goods sold.
Advertising Costs, Policy [Policy Text Block]	Advertising costs
	Costs associated with the advertising of our products are expensed as incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and development
	Research and development costs are charged to expense as incurred.  Research and development costs consist primarily of material and testing costs for research and development as well as research and development arrangements with unrelated third party research and development institutions.  These research and development arrangements usually involve one specific research and development project.  We may make non-refundable advances upon signing of these arrangements.  Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.  Such amounts are recognized as an expense as the related goods are delivered or as the related services are performed.  Management periodically evaluates whether the goods will be delivered or services will be rendered.  If management does not expect the goods to be delivered or services to be rendered, the capitalized advance payment is charged to expense.  Research and development expense was $24,523 and $27,804 in 2014 and 2013, respectively and are classified as general and administrative on the consolidated statements of operations.
Stockholders' Equity, Policy [Policy Text Block]	Equity instruments issued to parties other than employees for acquiring goods or services
	We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  Currently such transactions are primarily awards of warrants to purchase common stock.
	The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model.
	The assumptions used to determine the fair value of our warrants are as follows:
	-	The expected life of warrants issued represents the period of time the warrants are expected to be outstanding.
	-	The expected volatility is generally based on the historical volatility of comparable companies’ stock over the contractual life of the warrant.
	-	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant.
	-	The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant.
Income Tax, Policy [Policy Text Block]	Income taxes
	We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our consolidated statements of income in the period that includes the enactment date.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in our consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.  Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense.
	The tax years that are open to examination are 2011, 2012, 2013 and 2014.
Earnings Per Share, Policy [Policy Text Block]	Net loss per common share
	Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Convertible preferred stock, options and warrants to purchase our common stock as well as debt which are convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2014 and 2013. The following table presents a reconciliation of basic loss per share and excluded dilutive securities:
			For the Years Ended
			2014			2013
	Numerator:
	Net loss allocable to common stockholders		$	(2,296,591	)	$	(3,192,427	)
	Denominator:
	Weighted-average common shares outstanding			9,442,352			7,533,540
	Basic and diluted net loss per share		$	(0.24	)	$	(0.42	)
	Common stock warrants			7,111,027			4,058,050
	Series A convertible preferred stock			2,008,070			2,819,690
	Stock options			2,976,670			2,352,099
	Convertible debt including interest			1,317,604			932,332
	Excluded dilutive securities			13,413,371			10,162,171
Reclassification, Policy [Policy Text Block]	Reclassifications
	Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation.
Segment Reporting, Policy [Policy Text Block]	Segments
	We have determined that we operate in one segment for financial reporting purposes.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently issued accounting pronouncements
	In May 2014, the FASB issued new accounting guidance related to revenue recognition. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for Entia beginning January 1, 2017 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. We are evaluating the impact of adopting this new accounting standard on our financial statements.

NOTE_2_SUMMARY_OF_SIGNIFICANT_1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table presents a reconciliation of basic loss per share and excluded dilutive securities:
			For the Years Ended
			2014			2013
	Numerator:
	Net loss allocable to common stockholders		$	(2,296,591	)	$	(3,192,427	)
	Denominator:
	Weighted-average common shares outstanding			9,442,352			7,533,540
	Basic and diluted net loss per share		$	(0.24	)	$	(0.42	)
	Common stock warrants			7,111,027			4,058,050
	Series A convertible preferred stock			2,008,070			2,819,690
	Stock options			2,976,670			2,352,099
	Convertible debt including interest			1,317,604			932,332
	Excluded dilutive securities			13,413,371			10,162,171
Estimated Useful Lives [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Office equipment	3 years
	Production equipment	5 to 7 years
	Leasehold improvements	Lesser of lease term or useful life of improvement

NOTE_3_INVENTORY_Tables

NOTE 3 - INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following at:
		31-Dec-14			31-Dec-13
	Raw materials	$	202,591		$	240,750
	Finished goods		43,849			49,255
			246,440			290,005
	Less:  reserve for excess and obsolete inventory		(151,064	)		(151,064	)
		$	95,376		$	138,941

NOTE_4_PROPERTY_AND_EQUIPMENT_

NOTE 4 - PROPERTY AND EQUIPMENT (Tables) (Property, Plant and Equipment Table [Member])	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment Table [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, consists of the following at:
		31-Dec-14			31-Dec-13
	Office equipment	$	27,507		$	26,284
	Production equipment		86,999			83,615
	Leasehold improvements		16,328			16,328
			130,834			126,227
	Less:  accumulated depreciation		(87,687	)		(64,082	)
		$	43,147		$	62,145

NOTE_5_PATENTS_AND_LICENSES_NE1

NOTE 5 - PATENTS AND LICENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The gross carrying amounts and accumulated amortization related to these intangible assets consist of the following at:
		31-Dec-14			31-Dec-13
	Licenses and amortizable patents	$	207,244		$	234,324
	Unamortized patents		166,159			125,301
	Accumulated amortization		(30,569	)		(16,127	)
	Patents and Licenses, net	$	342,834		$	343,498

NOTE_6_ACCOUNTS_PAYABLE_AND_AC1

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses (included with accounts payable) consisted of the following at:
		31-Dec-14		31-Dec-13
	Executive compensation	$	153,432	$	476,368
	Other accruals		19,725		60,671
		$	173,157	$	537,039

NOTE_7_NOTES_PAYABLE_Tables

NOTE 7 - NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes payable consists of the following at:
		31-Dec-14		31-Dec-13
	Notes payable - current
	7.85% unsecured, $781 due monthly	$	2,304	$	1,964
	4.15% unsecured, $2,678 due monthly		-		21,824
	4.15% unsecured, $3,436 due monthly		23,726		-
	10.00% unsecured, interest only, due on demand		25,000		-
		$	51,030	$	23,788
		31-Dec-14		31-Dec-13
	Convertible notes payable, net
	8%, unsecured due on demand (net of discount related to beneficial conversion feature of $0 in 2014 and $49,004 in 2013), convertible into common stock at $0.45 per share.  This note was converted into common stock during December 2014.	$	-	$	263,496
	8% secured due on December 26, 2015 (net of discount related to beneficial conversion feature of $7,746 in 2014 and $12,300 in 2013), convertible into preferred stock at $5.00 per share.		42,254		37,700
	6% unsecured, convertible into common stock at $2.00 per share, due on demand		50,000		50,000
	8% unsecured due August 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $40,552 in 2013), convertible into common stock at an average price of $0.205 per share  This note was converted into 419,355 shares of common stock during August 2014.		-		22,448
	10% unsecured due March 2015 (net of discount related to warrants of $2,362 in 2014 and $0 in 2013) convertible price not yet determined		22,638		-
	10% unsecured due April 2015 (net of discount related to warrants of $9,800 in 2014 and $0 in 2013) convertible price not yet determined		90,200		-
	10% unsecured due April 2015 (net of discount related to warrants of $1,377 in 2014 and $0 in 2013) convertible price not yet determined		8,623		-
	8% unsecured due April 2015 (net of discount related to beneficial conversion feature of $11,968 in 2014 and $40,552 in 2013), convertible price not yet determined		30,532		-
	8% unsecured due May 2015 (net of discount related to beneficial conversion feature of $19,190 in 2014 and $0 in 2013), convertible price not yet determined		33,810		-
	10% unsecured due December 2015 (net of discount related to warrants of $4,620 in 2014 and $0 in 2013) convertible price not yet determined		25,380		-
	10% unsecured due December 2015 (net of discount related to warrants of $1,727 in 2014 and $0 in 2013) convertible price not yet determined		8,273		-
	10% unsecured due October 2015 (net of discount related to warrants of $1,805 in 2014 and $0 in 2013) convertible price not yet determined		8,195		-
	10% unsecured due October 2015 (net of discount related to warrants of $4,512 in 2014 and $0 in 2013) convertible price not yet determined		20,488		-
	8% unsecured due September 2015 (net of discount related to beneficial conversion feature of $36,247 in 2014 and $0 in 2013), convertible price not yet determined		17,253		-
		$	357,646	$	373,644
		31-Dec-14		31-Dec-14
	Convertible notes payable, net related party
	0% unsecured due March 30, 2014 (net of discount related to beneficial conversion feature of $0 in 2014 and $16,573 in 2013) convertible into common stock at $0.65 per share.  This note was paid off on March 31, 2014.	$	-	$	23,427
	0% unsecured due November 2015 (net of discount related to beneficial conversion feature of $2,738 in 2014 and $0 in 2013 and net of discount related to warrants of $2,863 in 2014 and $0 in 2013 and convertible into common stock at $0.30 per share.	$	9,399	$	-
		$	9,399	$	23,427

NOTE_9_STOCKHOLDERS_EQUITY_DEF1

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the option grants were calculated at the date of the grants using the Black-Scholes option pricing model with the following assumptions:
			31-Dec-14				31-Dec-13
	Expected dividend yield			-				-
	Expected stock price volatility			182.94%-216.96	%			216.96% - 236.55	%
	Risk-free interest rate			0.28% - 1.91	%			0.95% - 2.47	%
	Expected term (in years)		3 - 7 years				5 - 10 years
	Weighted-average granted date fair value		$	0.52			$	0.45
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of option activity under the stock option plan as of December 31, 2014, and changes during the year then ended is presented below:
												Weighted
										Weighted		Average
										Average		Remaining		Aggregate
			Number of				Exercise Price			Exercise		Contractual Term		Intrinsic
			Shares				Range			Price		(Years)		Value
	Outstanding, December 31, 2012			1,202,099			$	0.40 - $1.00		$	0.56		7.74		-
	Exercisable, December 31, 2012			830,504			$	0.40 - $1.00		$	0.57		8.19		-
	Granted			1,150,000			$	0.38 - $0.81		$	0.47		8.07		-
	Exercised			-				-		$	-		-		-
	Expired			-				-		$	-		-		-
	Outstanding, December 31, 2013			2,352,099			$	0.38 - $1.00		$	0.51		7.9		199,505
	Exercisable, December 31, 2013			1,810,344			$	0.38 - $1.00		$	0.52		7.88		138,707
	Granted			624,571			$	0.40-$0.75		$	0.52		6.49		-
	Exercised			-				-		$	-		-		-
	Expired/Forfeited			110,200			$	0.40-$0.50		$	0.48		9.51		-
	Outstanding, December 31, 2014			2,866,470			$	0.30 - $1.00		$	0.48		8.96		-
	Exercisable, December 31, 2014			2,321,001			$	0.38 - $1.00		$	0.47		9.5		-
Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Table Text Block]	The range of exercise prices for options outstanding under the 2010 Stock Incentive Plan at December 31, 2014 are as follows:
	Number of				Exercise
	shares				Price
		300,000			$	0.3
		55,000			$	0.38
		1,176,670			$	0.4
		30,000			$	0.42
		20,000			$	0.44
		10,000			$	0.45
		731,800			$	0.5
		160,000			$	0.6
		15,000			$	0.62
		120,000			$	0.75
		10,000			$	0.81
		200,000			$	0.85
		38,000			$	1
		2,866,470
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding warrants to purchase common stock are as follows:
	Date of Issue		31-Dec-14				Exercise Price			Expiration
	14-Dec			2,183,867			$	0.01 - $0.30		Dec-19
	14-Nov			1,875			$	0.2		Nov-21
	14-Oct			636,126			$	0.01 - $1.00		10/2017 - 10/2021
	14-Sep			316,208			$	0.001 - $1.00		09/2017 - 09/2024
	14-Aug			80,000			$	0.50 - $1.00		8/2017 - 8/2019
	14-Jun			15,000			$	0.5		Jun-19
	14-Apr			110,000				1		Apr-17
	14-Mar			38,332			$	0.40 - $1.00		03/2017 - 02/2024
	14-Jan			33,943			$	0.60 - $0.80		01/2019 - 01/2021
	As of December 2013			4,500,896			$	0.36 - $10.00		05/2015 - 10/2024
	Total			7,916,247
	Less:
	Expired			805,220
	Exercised			-
	Total			7,111,027
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	In determining the fair value of warrants, we employed the following key assumptions:
			31-Dec-14				31-Dec-13
	Risk-Free interest rate			0.28% - 2.97	%			0.95% - 3.32	%
	Expected dividend yield			0	%			0	%
	Volatility			182.81% - 222.30	%			216.48% - 239.20	%
	Expected life		3 - 10 years				3 - 10 years

NOTE_10_INCOME_TAXES_Tables

NOTE 10 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The components of our deferred tax assets/liabilities as of December 31, are as follows:
		2014			2013
	Deferred tax assets:
	Reserves and accruals	$	114,000		$	188,000
	Net operating loss carryforwards		1,472,000			1,149,000
	Total deferred tax assets:		1,586,000			1,337,000
	Deferred tax liabilities:
	Depreciation and amortization		8,000			11,000
	Net deferred tax assets before valuation allowance		1,578,000			1,326,000
	Less:  Valuation allowance		(1,578,000	)		(1,326,000	)
	Net deferred tax assets	$	-		$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation between the amount of income tax benefit determined by applying the applicable U.S. statutory income tax rate to pre-tax loss for the years ended December 31, is as follows:
		2014			2013
	Federal Statutory Rate	$	(781,000	)	$	(1,056,000	)
	Nondeductible expenses		529,000			683,000
	Change in allowance on deferred tax assets		(252,000	)		(373,000	)
		$	-		$	-

NOTE_1_ORGANIZATION_AND_OPERAT1

NOTE 1 - ORGANIZATION AND OPERATIONS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure Text Block [Abstract]
Cash and Cash Equivalents, at Carrying Value	$99,462	$36,886	$13,081

NOTE_2_SUMMARY_OF_SIGNIFICANT_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 23, 2013
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Allowance for Doubtful Accounts Receivable	$30,022	$2,526
Impairment of Intangible Assets, Finite-lived		288,454
Shipping, Handling and Transportation Costs	34,286	31,996
Research and Development Expense	24,523	27,804
Number of Operating Segments	1
Domestic Patents [Member] | Minimum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Domestic Patents [Member] | Maximum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Foreign Patents [Member] | Minimum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Foreign Patents [Member] | Maximum [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Patents [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life			15 years
Impairment of Intangible Assets, Finite-lived	$27,080

NOTE_2_SUMMARY_OF_SIGNIFICANT_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Property, Plant and Equipment, Estimated Useful Lives	12 Months Ended
	Dec. 31, 2014
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	Lesser of lease term or useful life of improvement

NOTE_2_SUMMARY_OF_SIGNIFICANT_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Net loss allocable to common stockholders (in Dollars)	($2,296,591)	($3,192,427)
Weighted-average common shares outstanding	9,442,352	7,533,540
Basic and diluted net loss per share (in Dollars per share)	($0.24)	($0.42)
Excluded dilutive securties	13,413,371	10,162,171
Warrant [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Excluded dilutive securties	7,111,027	4,058,050
Convertble Preferred Shares [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Excluded dilutive securties	2,008,070	2,819,690
Equity Option [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Excluded dilutive securties	2,976,670	2,352,099
Convertible Debt Securities [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Excluded dilutive securties	1,317,604	932,332

NOTE_3_INVENTORY_Details

NOTE 3 - INVENTORY (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Provision for Other Losses	$0	$0

NOTE_3_INVENTORY_Details_Sched

NOTE 3 - INVENTORY (Details) - Schedule of Inventory (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule of Inventory [Abstract]
Raw materials	$202,591	$240,750
Finished goods	43,849	49,255
	246,440	290,005
Less: reserve for excess and obsolete inventory	-151,064	-151,064
	$95,376	$138,941

NOTE_4_PROPERTY_AND_EQUIPMENT_1

NOTE 4 - PROPERTY AND EQUIPMENT (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation	$23,605	$25,327

NOTE_4_PROPERTY_AND_EQUIPMENT_2

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$130,834	$126,227
Less: accumulated depreciation	-87,687	-64,082
	43,147	62,145
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	27,507	26,284
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	86,999	83,615
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$16,328	$16,328

NOTE_5_PATENTS_AND_LICENSES_NE2

NOTE 5 - PATENTS AND LICENSES, NET (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 23, 2013	1-May-13
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$27,080	$288,454
Patents and Licenses [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Indefinite-lived Intangible Assets Acquired		288,454
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	27,080	288,454
Patents [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life			15 years
Finite-Lived Intangible Assets, Gross	166,159	125,301	31,325
Licensing Agreements [Member] | Minimum [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Licensing Agreements [Member] | Maximum [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	17 years
Licensing Agreements [Member]
NOTE 5 - PATENTS AND LICENSES, NET (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life				15 years
Finite-Lived Intangible Assets, Gross	207,244	234,324		150,000
Impairment of Intangible Assets (Excluding Goodwill)	14,442	10,663
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	13,488
Finite-Lived Intangible Assets, Amortization Expense, Year Two	13,488
Finite-Lived Intangible Assets, Amortization Expense, Year Three	13,488
Finite-Lived Intangible Assets, Amortization Expense, Year Four	13,488
Finite-Lived Intangible Assets, Amortization Expense, Year Five	13,488
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	$109,235

NOTE_5_PATENTS_AND_LICENSES_NE3

NOTE 5 - PATENTS AND LICENSES, NET (Details) - Schedule of Finite-Lived Intangible Assets (USD $)	Dec. 31, 2014	Dec. 31, 2013	1-May-13	Jul. 23, 2013
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	($30,569)	($16,127)
Patents and Licenses, net	342,834	343,498
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangilble assets, gross	207,244	234,324	150,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangilble assets, gross	$166,159	$125,301		$31,325

NOTE_6_ACCOUNTS_PAYABLE_AND_AC2

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)	12 Months Ended		3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014
NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Original Debt, Amount	$1,711,054	$414,404
Conversion of Accrued Compensation [Member]
NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price			$0.30
Debt Conversion, Converted Instrument, Shares Issued			2,592,570
Debt Conversion, Original Debt, Amount			777,770
Warrants, Term of Warrants			10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			306,208
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.00
Warrants, Fair Value of Warrants, Granted			$91,863

NOTE_6_ACCOUNTS_PAYABLE_AND_AC3

NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
Schedule of Accrued Liabilities [Abstract]
Executive compensation	$153,432	$476,368
Other accruals	19,725	60,671
	$173,157	$537,039

NOTE_7_NOTES_PAYABLE_Details

NOTE 7 - NOTES PAYABLE (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2010

Oct. 16, 2014

Sep. 02, 2014

Aug. 28, 2014

Apr. 27, 2014

Apr. 15, 2014

Mar. 28, 2014

Aug. 13, 2013

Dec. 13, 2014

Mar. 25, 2014

Mar. 31, 2014

Dec. 15, 2014

Aug. 11, 2014

Jul. 14, 2014

Jun. 13, 2014

Apr. 17, 2014

Feb. 03, 2014

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$1,711,054

$414,404

Gain (Loss) on Conversion of Debt

-169,187

0

Amortization of Debt Discount (Premium)

120,387

107,455

Gains (Losses) on Extinguishment of Debt

-100,000

0

Series A Preferred Stock [Member] | Convertible Notes Payable [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$5

Loans Payable [Member] | Debt Settled [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

312,500

Debt Conversion, Original Debt, Amount

76,427

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

864,282

Warrants, Fair Value of Warrants, Granted

374,464

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$0.01

$0.45

Warrants, Term of Warrants

5 years

Gain (Loss) on Conversion of Debt

-164,934

Loans Payable [Member] | Note Payable 4 [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

25,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

10.00%

10.00%

Loans Payable [Member] | Minimum [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Term

1 year

Loans Payable [Member] | Maximum [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Term

18 years

Loans Payable [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

35,000

10,000

30,000

100,000

10,000

25,000

Warrants, Fair Value of Warrants, Granted

7,980

2,590

7,920

39,200

4,130

9,450

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$1

Warrants, Term of Warrants

3 years

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares)

1

Convertible Notes Payable [Member] | Convertible Notes 5, 6, 7, 11 and 12 [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Convertible Notes Payable [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

100,000

50,000

53,500

53,000

42,500

32,500

32,500

42,500

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

400,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$0.50

$2

Debt Instrument, Term

1 year

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$0.25

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

50,000

Class of Warrant or Rights, Granted (in Shares)

50,000

Debt Instrument, Unamortized Discount

8,450

Amortization of Debt Discount (Premium)

704

Gains (Losses) on Extinguishment of Debt

100,000

Debt Instrument, Convertible, Terms of Conversion Feature

If the note remains unpaid after one hundred eighty (180) days from the Issue date, the holder has the option to convert the principal and accrued interest into shares of our Company stock at a conversion price equal to 58% of the “trading price” as described in the note.

Line of Credit [Member] | Prime Rate [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

3.00%

Line of Credit [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

60,000

Line of Credit Facility, Interest Rate at Period End

6.25%

Line of Credit, Current

$16,179

Minimum [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$0.36

Maximum [Member]

NOTE 7 - NOTES PAYABLE (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$10

NOTE_7_NOTES_PAYABLE_Details_S

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (USD $)	Dec. 31, 2014	Dec. 31, 2013
Notes payable - current
Notes payable	$51,030	$23,788
Convertible notes payable, net
Convertible notes payable	357,646	373,644
Convertible notes payable, net related party
Related party convertible notes payable	9,399	23,427
Loans Payable [Member] | Note Payable 1 [Member]
Notes payable - current
Notes payable	2,304	1,964
Loans Payable [Member] | Note Payable 2 [Member]
Notes payable - current
Notes payable	0	21,824
Loans Payable [Member] | Convertible Note 3 [Member]
Notes payable - current
Notes payable	23,726	0
Loans Payable [Member] | Note Payable 4 [Member]
Notes payable - current
Notes payable	25,000	0
Convertible Notes Payable [Member] | Convertible Note 3 [Member]
Convertible notes payable, net
Convertible notes payable	50,000	50,000
Convertible Notes Payable [Member] | Convertible Note 1 [Member]
Convertible notes payable, net
Convertible notes payable	0	263,496
Convertible Notes Payable [Member] | Convertible Note 2 [Member]
Convertible notes payable, net
Convertible notes payable	42,254	37,700
Convertible Notes Payable [Member] | Convertible Note 4 [Member]
Convertible notes payable, net
Convertible notes payable	0	22,448
Convertible Notes Payable [Member] | Convertible Note 5 [Member]
Convertible notes payable, net
Convertible notes payable	22,638	0
Convertible Notes Payable [Member] | Convertible Note 6 [Member]
Convertible notes payable, net
Convertible notes payable	90,200	0
Convertible Notes Payable [Member] | Convertible Note 7 [Member]
Convertible notes payable, net
Convertible notes payable	8,623	0
Convertible Notes Payable [Member] | Convertible Note 8 [Member]
Convertible notes payable, net
Convertible notes payable	30,532	0
Convertible Notes Payable [Member] | Convertible Note 9 [Member]
Convertible notes payable, net
Convertible notes payable	33,810	0
Convertible Notes Payable [Member] | Convertible Note 10 [Member]
Convertible notes payable, net
Convertible notes payable	25,380	0
Convertible Notes Payable [Member] | Convertible Note 11 [Member]
Convertible notes payable, net
Convertible notes payable	8,273	0
Convertible Notes Payable [Member] | Convertible Note 12 [Member]
Convertible notes payable, net
Convertible notes payable	8,195	0
Convertible Notes Payable [Member] | Convertible Note 13 [Member]
Convertible notes payable, net
Convertible notes payable	20,488	0
Convertible Notes Payable [Member] | Convertible Note 14 [Member]
Convertible notes payable, net
Convertible notes payable	17,253	0
Convertible Notes Payable [Member] | Related Party Convertible Note 1 [Member]
Convertible notes payable, net related party
Related party convertible notes payable	0	23,427
Convertible Notes Payable [Member] | Related Party Convertible Note 2 [Member]
Convertible notes payable, net related party
Related party convertible notes payable	$9,399	$0

NOTE_7_NOTES_PAYABLE_Details_S1

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Aug. 28, 2014	Aug. 13, 2013
Loans Payable [Member] | Note Payable 1 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	7.85%	7.85%
Due monthly (in Dollars)	$781	$781
Loans Payable [Member] | Note Payable 2 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	4.15%	4.15%
Due monthly (in Dollars)	2,678	2,678
Loans Payable [Member] | Convertible Note 3 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	4.15%	4.15%
Due monthly (in Dollars)	3,436	3,436
Loans Payable [Member] | Note Payable 4 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%	10.00%	10.00%
Due	due on demand	due on demand
Loans Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%
Convertible Notes Payable [Member] | Convertible Note 3 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	6.00%	6.00%
Convertible into stock at (in Dollars per share)	$2	$2
Convertible Notes Payable [Member] | Convertible Note 1 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	8.00%	8.00%
Discount related to beneficial conversion feature (in Dollars)	0	49,004
Convertible into stock at (in Dollars per share)	$0.45	$0.45
Convertible Notes Payable [Member] | Convertible Note 2 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	8.00%	8.00%
Discount related to beneficial conversion feature (in Dollars)	7,746	12,300
Convertible into stock at (in Dollars per share)	$5	$5
Convertible Notes Payable [Member] | Convertible Note 4 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	8.00%	8.00%
Due	Aug-14	Aug-14
Discount related to beneficial conversion feature (in Dollars)	0	40,552
Convertible into stock at (in Dollars per share)	$0.21	$0.21
Convertible Notes Payable [Member] | Convertible Note 5 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%	10.00%
Due	Mar-15	Mar-15
Discount related to warrants (in Dollars)	2,362	0
Convertible Notes Payable [Member] | Convertible Note 6 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%	10.00%
Due	Apr-15	Apr-15
Discount related to warrants (in Dollars)	9,800	0
Convertible Notes Payable [Member] | Convertible Note 7 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%	10.00%
Due	Apr-15	Apr-15
Discount related to warrants (in Dollars)	1,377	0
Convertible Notes Payable [Member] | Convertible Note 8 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	8.00%	8.00%
Due	Apr-15	Apr-15
Discount related to beneficial conversion feature (in Dollars)	11,968	40,552
Convertible Notes Payable [Member] | Convertible Note 9 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	8.00%	8.00%
Due	May-15	May-15
Discount related to beneficial conversion feature (in Dollars)	19,190	0
Convertible Notes Payable [Member] | Convertible Note 10 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%	10.00%
Due	Dec-15	Dec-15
Discount related to warrants (in Dollars)	4,620	0
Convertible Notes Payable [Member] | Convertible Note 11 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%	10.00%
Due	Dec-15	Dec-15
Discount related to warrants (in Dollars)	1,727	0
Convertible Notes Payable [Member] | Convertible Note 12 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%	10.00%
Due	Oct-15	Oct-15
Discount related to beneficial conversion feature (in Dollars)	1,805	0
Convertible Notes Payable [Member] | Convertible Note 13 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	10.00%	10.00%
Due	Oct-15	Oct-15
Discount related to beneficial conversion feature (in Dollars)	4,512	0
Convertible Notes Payable [Member] | Convertible Note 14 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	8.00%	8.00%
Due	Sep-15	Sep-15
Discount related to beneficial conversion feature (in Dollars)	36,247	0
Convertible Notes Payable [Member] | Related Party Convertible Note 1 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	0.00%	0.00%
Due	30-Mar-14	30-Mar-14
Discount related to beneficial conversion feature (in Dollars)	0	16,573
Convertible into stock at (in Dollars per share)	$0.65	$0.65
Convertible Notes Payable [Member] | Related Party Convertible Note 2 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate	0.00%	0.00%
Due	Nov-15	Nov-15
Discount related to beneficial conversion feature (in Dollars)	2,738	0
Convertible into stock at (in Dollars per share)	$0.30	$0.30
Discount related to warrants (in Dollars)	$2,863	$0
Convertible Notes Payable [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest rate					8.00%
Convertible into stock at (in Dollars per share)				$0.25

NOTE_8_RELATED_PARTY_TRANSACTI1

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) (USD $)	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	0 Months Ended
	Dec. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2014	Jul. 01, 2014	Oct. 16, 2014	Sep. 02, 2014	Aug. 28, 2014	Apr. 27, 2014	Apr. 15, 2014	Mar. 28, 2014
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	525,000
Series A Preferred Stock [Member] | Director [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)		1,000
Proceeds from Issuance of Convertible Preferred Stock		$5,000
Series A Preferred Stock [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)			140,175
Proceeds from Issuance of Convertible Preferred Stock			700,875
Director [Member] | Loans Payable [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			0.00%
Debt Instrument, Face Amount			40,000
Director [Member] | Convertible Debt [Member] | Discount from Issuance of Warrants [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Unamortized Discount					5,445
Director [Member] | Convertible Debt [Member] | Discount from Beneficial Conversion Feature [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Unamortized Discount					7,545
Director [Member] | Convertible Debt [Member] | Note Extension [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Warrants, Term of Warrants				7 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	0.2			$0.20
Debt Instrument, Unamortized Discount	3,435			3,435
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	0.3			$0.30
Class of Warrant or Rights, Granted (in Shares)				15,000
Debt Instrument, Difference in Fair Value Related to Modification				27
Director [Member] | Convertible Debt [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					0.00%
Debt Instrument, Face Amount					15,000
Warrants, Term of Warrants					5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)					15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					$0.50
Debt Instrument, Convertible, Conversion Price (in Dollars per share)					$0.50
Loans Payable [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.00%			10.00%
Debt Instrument, Face Amount						$35,000	$10,000	$30,000	$100,000	$10,000	$25,000
Warrants, Term of Warrants	3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	1			$1

NOTE_9_STOCKHOLDERS_EQUITY_DEF2

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	26-May-11	Sep. 17, 2010
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Conversion of Stock, Shares Issued	811,620	250,000
Stock Issued During Period, Shares, New Issues	525,000
Debt Conversion, Original Debt, Amount (in Dollars)	$1,711,054	$414,404
Stock Issued During Period, Value, Issued for Services (in Dollars)	121,835	83,400
Stock Issued During Period, Value, New Issues (in Dollars)	225,000	700,875
Stock Issued During Period, Value, Purchase of Assets (in Dollars)		215,529
Warrants, Grants in Period, Weighted-Average Grant Date Fair Value (in Dollars per share)	$0.39	$0.45
Future Services [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	68,283
Stock Issued During Period, Value, Issued for Services (in Dollars)	44,250
Stock Issued for Services Rendered [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	189,700
Stock Issued During Period, Value, Issued for Services (in Dollars)	100,335
Stock Issued with Distributor Agreement [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	50,000
Stock Issued During Period, Value, Issued for Services (in Dollars)	21,500
Stock Issued for Consulting Agreements Signed in 2013 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services		53,500
Stock Issued During Period, Value, Issued for Services (in Dollars)		31,090
Stock Issued for Consulting Agreement Signed August 1, 2013 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services		9,000
Stock Issued During Period, Value, Issued for Services (in Dollars)		4,320
Stock Issued in Association with 2011 Employment Agreements [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Number of Officers		2
Stock Issued During Period, Shares, Share-based Compensation, Gross		76,396
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)		48,893
Series A Preferred Stock [Member] | Conversion of Accounts Payable [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		30,400
Debt Conversion, Original Debt, Amount (in Dollars)		152,001
Series A Preferred Stock [Member] | Conversion of Convertible Debt [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		26,494
Debt Conversion, Original Debt, Amount (in Dollars)		132,402
Series A Preferred Stock [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Preferred Stock, Shares Authorized	350,000	350,000	350,000
Preferred Stock, No Par Value (in Dollars per share)			$0.00
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)			$5
Preferred Stock, Conversion Basis			one-for-ten
Number of Investors	5
Conversion of Stock, Shares Converted	81,162	25,000
Stock Issued During Period, Shares, New Issues		140,175
Proceeds from Issuance of Convertible Preferred Stock (in Dollars)		700,875
Conversion of Accounts Payable [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	344,530
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)	132,928
Conversion of Convertible Debt [Member] | Principal [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)	590,882
Conversion of Convertible Debt [Member] | Interest [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)	83,247
Conversion of Convertible Debt [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	2,633,579
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)	933,284
Conversion of Accrued Compensation [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	2,592,570	264,158
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)	777,770	125,001
Number of Employees	2
Number of Officers		2
Licensing Agreements [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Stock Issued During Period, Shares, Purchase of Assets		200,000
Stock Issued During Period, Value, Purchase of Assets (in Dollars)		124,000
Minimum [Member] | 2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				4 years
Maximum [Member] | 2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				15 years
2010 Stock Incentive Plan [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				1,550,000
Share-based Compensation Arrangement by Share-based Payment Award, Description				an annual increase in shares of 50,000 as of January 1 of each year; commencing January 1, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,783,530
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$303,349
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	9 years

NOTE_9_STOCKHOLDERS_EQUITY_DEF3

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Expected dividend yield	0.00%	0.00%
Weighted-average granted date fair value (in Dollars per share)	$0.52	$0.45
Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Expected stock price volatility	182.94%	216.96%
Risk-free interest rate	0.28%	0.95%
Expected term (in years)	3 years	5 years
Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Expected stock price volatility	216.96%	236.55%
Risk-free interest rate	1.91%	2.47%
Expected term (in years)	7 years	10 years

NOTE_9_STOCKHOLDERS_EQUITY_DEF4

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Number of Shares (in Shares)	2,866,470	2,352,099	1,202,099
Options Outstanding, Weighted Average Exercise Price	$0.48	$0.51	$0.56
Options Outstanding, Weighted Average Remaining Contractual Term	8 years 350 days	7 years 328 days	7 years 270 days
Options Outstanding, Aggregate Intrinsic Value (in Dollars)		$199,505
Options Exercisable, Number of Shares (in Shares)	2,321,001	1,810,344	830,504
Options Exercisable, Weighted Average Exercise Price	$0.47	$0.52	$0.57
Options Exercisable, Weighted Average Remaining Contractual Term	9 years 6 months	7 years 321 days	8 years 69 days
Options Exercisable, Aggregate Intrinsic Value (in Dollars)		$138,707
Options Granted, Number of Shares (in Shares)	624,571	1,150,000
Options Granted, Weighted Average Exercise Price	$0.52	$0.47
Options Granted, Weighted Average Remaining Contractual Term	6 years 178 days	8 years 25 days
Options Exercised, Number of Shares (in Shares)	0	0
Options Expired, Number of Shares (in Shares)	110,200	0
Options Expired, Weighted Average Exercise Price	$0.48
Options Expired, Weighted Average Remaining Contractual Term	9 years 186 days
Minimum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Exercise Price	$0.30	$0.38	$0.40
Options Exercisable, Exercise Price	$0.38	$0.38	$0.40
Options Granted, Exercise Price	$0.40	$0.38
Options Expired, Exercise Price	$0.40
Maximum [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Stock Options, Activity [Line Items]
Options Outstanding, Exercise Price	$1	$1	$1
Options Exercisable, Exercise Price	$1	$1	$1
Options Granted, Exercise Price	$0.75	$0.81
Options Expired, Exercise Price	$0.50

NOTE_9_STOCKHOLDERS_EQUITY_DEF5

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	2,866,470	2,352,099	1,202,099
Options Exercisable at $0.30 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	300,000
Exercise Price (in Dollars per share)	0.3
Options Exercisable at $0.38 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	55,000
Exercise Price (in Dollars per share)	0.38
Options Exercisable at $0.40 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	1,176,670
Exercise Price (in Dollars per share)	0.4
Options Exercisable at $0.42 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	30,000
Exercise Price (in Dollars per share)	0.42
Options Exercisable at $0.44 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	20,000
Exercise Price (in Dollars per share)	0.44
Options Exercisable at $0.45 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	10,000
Exercise Price (in Dollars per share)	0.45
Options Exercisable at $0.50 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	731,800
Exercise Price (in Dollars per share)	0.5
Options Exercisable at $0.60 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	160,000
Exercise Price (in Dollars per share)	0.6
Options Exercisable at $0.62 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	15,000
Exercise Price (in Dollars per share)	0.62
Options Exercisable at $0.75 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	120,000
Exercise Price (in Dollars per share)	0.75
Options Exercisable at $0.81 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	10,000
Exercise Price (in Dollars per share)	0.81
Options Exercisable at $0.85 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	200,000
Exercise Price (in Dollars per share)	0.85
Options Exercisable at $1.00 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Share-based Compensation, Shares Outstanding under Stock Option Plans, by Exercise Price Range [Line Items]
Number of Options Oustanding	38,000
Exercise Price (in Dollars per share)	1

NOTE_9_STOCKHOLDERS_EQUITY_DEF6

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Schedule of Stockholders' Equity Note, Warrants (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Warrants granted, expiration		05/2015 - 10/2024
Warrants outstanding (in Shares)	7,916,247	4,500,896
Warrants outstanding, expiration		05/2015 - 10/2024
Expired (in Shares)	805,220
Exercised (in Shares)	0
Total (in Shares)	7,111,027
Warrants Issued December 2014 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	0.01
Warrants outstanding,exercise price	0.01
Warrants Issued December 2014 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	0.3
Warrants outstanding,exercise price	0.3
Warrants Issued December 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	2,183,867
Warrants granted, expiration	Dec-19
Warrants outstanding, expiration	Dec-19
Warrants Issued November 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	1,875
Warrants granted, exercise price	0.2
Warrants granted, expiration	Nov-21
Warrants outstanding,exercise price	0.2
Warrants outstanding, expiration	Nov-21
Warrants Issued October 2014 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	0.01
Warrants outstanding,exercise price	0.01
Warrants Issued October 2014 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	1
Warrants outstanding,exercise price	1
Warrants Issued October 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	636,126
Warrants granted, expiration	10/2017 - 10/2021
Warrants outstanding, expiration	10/2017 - 10/2021
Warrants Issued September 2014 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	0.001
Warrants outstanding,exercise price	0.001
Warrants Issued September 2014 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	1
Warrants outstanding,exercise price	1
Warrants Issued September 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	316,208
Warrants granted, expiration	09/2017 - 09/2024
Warrants outstanding, expiration	09/2017 - 09/2024
Warrants Issued August 2014 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	0.5
Warrants outstanding,exercise price	0.5
Warrants Issued August 2014 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	1
Warrants outstanding,exercise price	1
Warrants Issued August 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	80,000
Warrants granted, expiration	8/2017 - 8/2019
Warrants outstanding, expiration	8/2017 - 8/2019
Warrants Issued June 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	15,000
Warrants granted, exercise price	0.5
Warrants granted, expiration	Jun-19
Warrants outstanding,exercise price	0.5
Warrants outstanding, expiration	Jun-19
Warrants Issued April 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	110,000
Warrants granted, exercise price	1
Warrants granted, expiration	Apr-17
Warrants outstanding,exercise price	1
Warrants outstanding, expiration	Apr-17
Warrants Issued March 2014 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	0.4
Warrants outstanding,exercise price	0.4
Warrants Issued March 2014 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	1
Warrants outstanding,exercise price	1
Warrants Issued March 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	38,332
Warrants granted, expiration	03/2017 - 02/2024
Warrants outstanding, expiration	03/2017 - 02/2024
Warrants Issued January 2014 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	0.6
Warrants outstanding,exercise price	0.6
Warrants Issued January 2014 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price	0.8
Warrants outstanding,exercise price	0.8
Warrants Issued January 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants granted (in Shares)	33,943
Warrants granted, expiration	01/2019 - 01/2021
Warrants outstanding, expiration	01/2019 - 01/2021
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price		0.36
Warrants outstanding,exercise price		0.36
Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants granted, exercise price		10
Warrants outstanding,exercise price		10

NOTE_9_STOCKHOLDERS_EQUITY_DEF7

NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details) - Fair Value Measurements, Warrants, Valuation Assumptions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-Free interest rate	0.28%	0.95%
Volatility	182.81%	216.48%
Expected life	3 years	3 years
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-Free interest rate	2.97%	3.32%
Volatility	222.30%	239.20%
Expected life	10 years	10 years

NOTE_10_INCOME_TAXES_Details

NOTE 10 - INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$4,382,132
Operating Loss Carryforwards, Expiration Date	2026

NOTE_10_INCOME_TAXES_Details_S

NOTE 10 - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Reserves and accruals	$114,000	$188,000
Net operating loss carryforwards	1,472,000	1,149,000
Total deferred tax assets:	1,586,000	1,337,000
Deferred tax liabilities:
Depreciation and amortization	8,000	11,000
Net deferred tax assets before valuation allowance	1,578,000	1,326,000
Less: Valuation allowance	-1,578,000	-1,326,000
Net deferred tax assets	$0	$0

NOTE_10_INCOME_TAXES_Details_S1

NOTE 10 - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Federal Statutory Rate	($781,000)	($1,056,000)
Nondeductible expenses	529,000	683,000
Change in allowance on deferred tax assets	-252,000	-373,000
	$0	$0

NOTE_11_COMMITMENTS_AND_CONTIN1

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) (USD $)	4 Months Ended	7 Months Ended	8 Months Ended	12 Months Ended		18 Months Ended
	Sep. 30, 2012	Dec. 31, 2014	31-May-14	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Apr. 04, 2012
							sqft
Commitments and Contingencies Disclosure [Abstract]
Area of Real Estate Property (in Square Feet)							13,081
Operating Leases, Rent Expense, Minimum Rentals	$0	$3,343	$3,260			$3,160
Deferred Rent Credit		1,279		1,279	6,555
Operating Leases, Future Minimum Payments Due, Next Twelve Months		47,988		47,988
Operating Leases, Future Minimum Payments, Due in Two Years		27,992		27,992
Operating Leases, Rent Expense, Net				$47,988	$43,497

NOTE_12_CONCENTRATIONS_AND_CRE1

NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Five Vendors [Member | Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	46.00%	54.00%
Five Vendors [Member | Liabilities, Total [Member] | Supplier Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	4.00%	1.00%
Five Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	47.00%	50.00%
Five Customers [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 12 - CONCENTRATIONS AND CREDIT RISK (Details) [Line Items]
Concentration Risk, Percentage	81.00%	31.00%

NOTE_13_SUBSEQUENT_EVENTS_Deta

NOTE 13 - SUBSEQUENT EVENTS (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Feb. 14, 2015	Feb. 24, 2015	Feb. 19, 2015	Jan. 30, 2015	Jan. 15, 2015	Jan. 09, 2015	Jan. 02, 2015
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount	$1,711,054	$414,404
Amortization of Debt Discount (Premium)	120,387	107,455
Interest Paid	843	1,064
Proceeds from Issuance or Sale of Equity	225,000	700,875
Stock Issued During Period, Shares, New Issues (in Shares)	525,000
Interest [Member] | Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount			1,700
Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Original Debt, Amount			27,500		25,000		15,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			357,843		318,471		170,068
Amortization of Debt Discount (Premium)			11,968	19,190
Repayments of Debt				28,000
Interest Paid				2,171
Payments of Debt Extinguishment Costs				12,329
Proceeds from Issuance or Sale of Equity						$30,000		$20,000	$20,000
Stock Issued During Period, Shares, New Issues (in Shares)						150,000		100,000	100,000
Class of Warrant or Rights, Granted (in Shares)						30,000		20,000	20,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$0.30		$0.30	$0.30
Warrants, Term of Warrants						5 years		5 years	5 years